|
|
Vaccine Detail
|
Whole tumor cell-based leukemia vaccine |
| Vaccine Information |
- Vaccine Name: Whole tumor cell-based leukemia vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007743
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: CLL tumor antigens (Burkhardt and Wu, 2013)
- Immunization Route: subcutaneous injection
- Description: Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect. (Burkhardt and Wu, 2013)
|
| Host Response |
|
|
| References |
Burkhardt and Wu, 2013: Burkhardt UE, Wu CJ. Boosting leukemia-specific T cell responses in patients following stem cell transplantation. Oncoimmunology. 2013; 2(11); e26587. [PubMed: 24482749].
|
|
